Navigation Links
Nile Therapeutics Receives Positive NASDAQ Panel Decision
Date:3/2/2011

tide, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rationally designed natriuretic peptide. More information on Nile can be found at http://www.nilethera.com.

Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Nile's ability to regain compliance with NASDAQ's listing requirements are forward-looking statements. Nile may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on Nile's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Nile makes. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that Nile makes include whether the price of Nile's common stock will close at or above $1.00 for at least 10 consecutive business days prior to May 31, 2011, Nile's need to raise additional capital to fund its product development programs to completion, Nile's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in greater detail in the reports Nile files with the Securities and Exchange Commission, including those described under the caption "Risk Factors" in Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2009 filed with the Securities and Exchange Commission on March 3, 2010. Nile is providing this information as of the dat
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... SANTA CLARA, Calif. , May 21, ... a game-changing embedded-ultrasound platform, today announced the ... Toolkit that allows complete network-based communications with ... demonstrate its latest embedded-ultrasound technology, including this ... Sao Paulo, Brazil ...
(Date:5/21/2013)... , May 21, 2013 Hurel Corporation ... and microfluidic cell-based assay platforms, today announced the appointment ... DABT to the Company,s Board of Directors. Dr. MacDonald ... of the Schering-Plough Research Institute ("SPRI"), which was the ... acquisition by Merck & Co. in 2009. ...
(Date:5/21/2013)... -- Vasomedical, Inc. (OTC BB: VASO) (the "Company"), a diversified medical ... medical devices and in the domestic sale of diagnostic imaging ... , President and CEO of Vasomedical, Inc. will present at ... 30, 2013 in New York City ... presentation is scheduled to begin at 9:30 a.m. EDT. ...
Breaking Medicine Technology:Cephasonics Unveils Next-Generation Wireless-Imaging Technology for cQuest Ultrasound Hardware Platforms 2Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDonald to Board of Directors 2Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2
... 2012  Islet Sciences, Inc., (OTCBB: ISLT) a biotechnology company ... technologies in the field of transplantation therapy for patients ... technology from Yale University. "In the ... Herold and his colleagues at Yale University School of ...
... /PRNewswire-iReach/ -- PharmacyGPO, Inc.,  a ... the United States, today announced a three-year agreement ... (Photo: http://photos.prnewswire.com/prnh/20120507/CG01217 ) ... Smith, a leading national wholesaler, will be the ...
Cached Medicine Technology:Islet Sciences Announces Exclusive License Agreement with Yale University to Commercialize an Early Beta Cell Destruction and Diabetes Diagnostic 2PharmacyGPO Buying Group Selects H. D. Smith as Primary National Distributor 2PharmacyGPO Buying Group Selects H. D. Smith as Primary National Distributor 3
(Date:5/21/2013)... CINCINNATIUsing the Department of Defense Serum Repository (DoDSR), University ... biomarkers for inflammatory bowel disease (IBD), which could help ... not yet shown symptoms. , This finding, the first ... MD, is being presented via podium presentation by staff ... Disease Week 2013, being held May 18-21 in Orlando, ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Today, Zane ... HSA and FSA accounts. Zane Benefits, which provides ... benefits, is the leader in defined contribution ... arrangements . , According to Zane Benefits’ website, the ... was signed into law in 2010 and impacts many ...
(Date:5/21/2013)... 2013 The American Diabetes Association ( ... the United States of America are affected with peripheral ... great risk of developing peripheral neuropathy which unfortunately makes ... ADA further goes on saying that the disease usually ... 2 million new cases are diagnosed every year in ...
(Date:5/21/2013)... Reporter , , TUESDAY, May 21 (HealthDay News) -- Swollen ... apnea in children, and while removing them did not ... did help them with sleep, behavior and quality of ... a condition that causes abnormal pauses in breathing during ... with the surgery, and those improvements were likely responsible ...
(Date:5/21/2013)... In adults with chronic kidney disease (CKD), cigarette ... progression and transplant failure. Now, a first-of-its-kind study by ... has found a possible similar effect in children with ... , The study of 366 children aged 1 to ... of secondhand smoke exposure in CKD, according to lead ...
Breaking Medicine News(10 mins):Health News:Biomarkers discovered for inflammatory bowel disease 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3Health News:Neuracel Aims to Reduce Peripheral Neuropathy Pain 2Health News:Removing Tonsils Helps Kids With Sleep Apnea, Study Finds 2Health News:Removing Tonsils Helps Kids With Sleep Apnea, Study Finds 3Health News:Exposure to Secondhand Smoke May Lead to Worsening of Pediatric Kidney Disease; Pediatric Nephrology Publishes Dayton Children’s, Johns Hopkins Joint Study 2Health News:Exposure to Secondhand Smoke May Lead to Worsening of Pediatric Kidney Disease; Pediatric Nephrology Publishes Dayton Children’s, Johns Hopkins Joint Study 3
... men enrolled in an active surveillance program for prostate ... fared just as well as men who opted to ... during surveillance showed high-grade cancer. Active surveillance, or ... tumors are considered small, low-grade and at low risk ...
... A psychological intervention program designed for breast cancer patients reduces ... shows. The study is the latest in a series ... program that teaches patients how to cope with the disease ... survival. Researchers at Ohio State,s Comprehensive Cancer Center had ...
... guidelines for best treatment practices are common, they ... to them in clinical practice, according to a ... medicine researchers. In the study, UC associate ... his colleagues used national standards for treatment of ...
... -- City of Hope researchers received approval from the ... first-in-human study of a neural stem cell-based therapy targeting ... tumor. Karen S. Aboody, M.D., associate professor in City ... that developed this treatment strategy. Jana Portnow, M.D., assistant ...
... the University of Cincinnati (UC) and the Cincinnati ... received funding to study the care processes that ... beginning dialysis. Timmy Lee, MD, UC Health ... the study, was awarded the National Kidney Foundation,s ...
... cats have them and whales have some, too. Neurons, those ... our spinal cords to the tips of our toes, paws ... journal Cell , scientists from the Harvard Medical School, ... found a new way by which nerve cells relay information ...
Cached Medicine News:Health News:Delay in surgery not likely to worsen tumors in men with low-risk prostate cancer 2Health News:Intervention program helps breast cancer patients live longer after recurrence 2Health News:Intervention program helps breast cancer patients live longer after recurrence 3Health News:'Knowledge translation' keeps treatment current 2Health News:FDA approves first human neural stem cell clinical trial to treat brain tumors 2Health News:FDA approves first human neural stem cell clinical trial to treat brain tumors 3Health News:New research examines care practices in place for dialysis patients 2
ABS2000 is an automated system that can handle more workload. It allows accurate detection of antibodies that can be missed out by manual testing....
The ScanGel® automatic readings are done with a high resolution color video camera. Images can be stored and printed....
... System for endovenous occlusion of varicose ... with a family of disposable catheters to ... energy. With VNUS ClosurePlus , ... catheters, physicians can treat incompetent saphenous, ...
Thesystem combines an exclusive dual light-source design and a versatile sample compartment to provide solid, reliable performance....
Medicine Products: